Biobanking for better healthcare

Riegman, Peter; Morente, Manuel; Betsou, Fay; Blasio, Pasquale De; Geary, Peter

doi:10.1016/j.molonc.2008.07.004

Cited by 239 publications

(155 citation statements)

References 31 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…identical treatment, age-matched, and diseasematched) should establish whether the combination of these markers can contribute to a more accurate treatment of UCs. However, the acquisition of a large series of cases associated with high quality samples with clinical data is not a trivial task as it will necessitate the involvement of many laboratories in different countries in a large scale multicenter research project, a challenging prospect by all accounts (63).…”

Section: Discussionmentioning

confidence: 99%

Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer

Moreira

Ohlsson

Gromov

et al. 2010

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical followup. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.Molecular & Cellular Proteomics 9:161-177, 2010.

show abstract

Section: Discussionmentioning

confidence: 99%

Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer

Moreira

Ohlsson

Gromov

et al. 2010

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…Thus, during the course of an experiment variations or delays in sample retrieval and processing can potentially alter the quantitative characteristics of the phosphoproteome (17,18,22). Similar problems could in principle occur in a clinical environment where several hours may elapse from patient sample collec-tion to processing or preservation (16,17,23). Delays because of ethical and practical considerations may also affect collection and preservation of post-mortem samples (24,25).…”

mentioning

confidence: 99%

Environmental Stress Affects the Activity of Metabolic and Growth Factor Signaling Networks and Induces Autophagy Markers in MCF7 Breast Cancer Cells

Casado

Bilanges

Rajeeve

et al. 2014

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Phosphoproteomic techniques are contributing to our understanding of how signaling pathways interact and regulate biological processes. This technology is also being used to characterize how signaling networks are remodeled during disease progression and to identify biomarkers of signaling pathway activity and of responses to cancer therapy. A potential caveat in these studies is that phosphorylation is a very dynamic modification that can substantially change during the course of an experiment or the retrieval and processing of cellular samples. Here, we investigated how exposure of cells to ambient conditions modulates phosphorylation and signaling pathway activity in the MCF7 breast cancer cell line. About 1.5% of 3,500 sites measured showed a significant change in phosphorylation extent upon exposure of cells to ambient conditions for 15 min. The effects of this perturbation in modifying phosphorylation patterns did not involve random changes due to stochastic activation of kinases and phosphatases. Instead, exposure of cells to ambient conditions elicited an environmental stress reaction that involved a coordinated response to a metabolic stress situation, which included: (1) the activation of AMPK; (2) the inhibition of PI3K, AKT, and ERK; (3) an increase in markers of protein synthesis inhibition at the level of translation elongation; and (4) an increase in autophagy markers. We also observed that maintaining cells in ice modified but did not completely abolish this metabolic stress response. In summary, exposure of cells to ambient conditions affects the activity of signaling networks previously implicated in metabolic and growth factor signaling. Mass spectrometry data have been deposited to the ProteomeXchange with identifier PXD000472. Molecular

show abstract

“…Harmonization in biobank governance is important to international cooperation and networking in biobank research. 19 To this end, a systematically derived template for access policies might be more useful than or at least complement improved guidelines. Such a template would include precise text passages for potentially relevant access criteria and allow a quick adjustment for biobank-specific characteristics, national laws or other local sensitivities.…”

Section: Discussionmentioning

confidence: 99%

“…We did not restrict our analysis to one specific type of biobank (eg, population banks, disease-specific biobanks). 19 Only access policies in English or German were included.…”

Section: Search For Access Policiesmentioning

confidence: 99%

Access policies in biobank research: what criteria do they include and how publicly available are they? A cross-sectional study

et al. 2016

View full text Add to dashboard Cite

Access policies of biobanks specify the governance of sample and data sharing. Basic guidance on relevant access criteria exists, but so far little is known about their public availability and what criteria for access and prioritization they actually include. Access policies were gathered by hand searching the websites of biobanks identified via registries (eg, BBMRI and P3G), and by additional search strategies. Criteria for access and prioritization were synthesized by thematic analysis. Of 523 biobank websites screened, 9% included a publicly available access policy. With all applied search strategies, we finally retrieved 74 access policies. Thematic analysis resulted in 62 different access criteria in three main categories: (a) scientific quality, (b) value and (c) ethical soundness. 'Scientific quality' criteria were mentioned in 70% of all policies, 'value' criteria in 33% and 'ethical soundness' criteria in 73%. Criteria for prioritization were specified in 27% of all policies. Access policies differed broadly in number, specification and operationalization of the included access criteria. In order to make biobank research more effective, efficient and trustworthy, access policies should be more available to the public. Furthermore, access policies should aim for precise and more harmonized wording of access criteria. From a public and governance perspective, the issue of how to prioritize access to scarce samples should form part of access policies.

show abstract

Biobanking for better healthcare

Cited by 239 publications

References 31 publications

Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer

Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer

Environmental Stress Affects the Activity of Metabolic and Growth Factor Signaling Networks and Induces Autophagy Markers in MCF7 Breast Cancer Cells

Access policies in biobank research: what criteria do they include and how publicly available are they? A cross-sectional study

Contact Info

Product

Resources

About